25 XP   0   0   10

CureVac NV
Buy, Hold or Sell?

Let's analyse Curevac together

PenkeI guess you are interested in CureVac NV. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of CureVac NV. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about CureVac NV

I send you an email if I find something interesting about CureVac NV.

Quick analysis of Curevac (30 sec.)










What can you expect buying and holding a share of Curevac? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.54
Expected worth in 1 year
$-0.42
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$-2.95
Return On Investment
-121.0%

For what price can you sell your share?

Current Price per Share
$2.44
Expected price per share
$0 - $3.26
How sure are you?
50%

1. Valuation of Curevac (5 min.)




Live pricePrice per Share (EOD)

$2.44

Intrinsic Value Per Share

$-25.34 - $-30.26

Total Value Per Share

$-22.81 - $-27.72

2. Growth of Curevac (5 min.)




Is Curevac growing?

Current yearPrevious yearGrowGrow %
How rich?$567.7m$732.9m-$165.2m-29.1%

How much money is Curevac making?

Current yearPrevious yearGrowGrow %
Making money-$265.1m-$438.3m$173.1m65.3%
Net Profit Margin-369.4%-399.8%--

How much money comes from the company's main activities?

3. Financial Health of Curevac (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#93 / 1016

Most Revenue
#122 / 1016

Most Profit
#1010 / 1016

Most Efficient
#712 / 1016

What can you expect buying and holding a share of Curevac? (5 min.)

Welcome investor! Curevac's management wants to use your money to grow the business. In return you get a share of Curevac.

What can you expect buying and holding a share of Curevac?

First you should know what it really means to hold a share of Curevac. And how you can make/lose money.

Speculation

The Price per Share of Curevac is $2.44. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Curevac.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Curevac, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.54. Based on the TTM, the Book Value Change Per Share is $-0.74 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.11 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Curevac.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.18-48.5%-1.18-48.5%-1.96-80.2%-0.91-37.4%-0.91-37.4%
Usd Book Value Change Per Share-0.74-30.2%-0.74-30.2%-0.11-4.5%0.5120.8%0.5120.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.74-30.2%-0.74-30.2%-0.11-4.5%0.5120.8%0.5120.8%
Usd Price Per Share6.03-6.03-34.31-24.28-24.28-
Price to Earnings Ratio-5.09--5.09--17.53--30.94--30.94-
Price-to-Total Gains Ratio-8.17--8.17--315.54--100.37--100.37-
Price to Book Ratio2.38-2.38-10.48-7.37-7.37-
Price-to-Total Gains Ratio-8.17--8.17--315.54--100.37--100.37-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.44
Number of shares409
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.740.51
Usd Total Gains Per Share-0.740.51
Gains per Quarter (409 shares)-301.83207.38
Gains per Year (409 shares)-1,207.33829.53
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1207-12170830820
20-2415-2424016591650
30-3622-3631024892480
40-4829-4838033183310
50-6037-6045041484140
60-7244-7252049774970
70-8451-8459058075800
80-9659-9666066366630
90-10866-10873074667460
100-12073-12080082958290

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.05.00.00.0%0.05.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%2.03.00.040.0%2.03.00.040.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.05.00.0%0.00.05.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%2.03.00.040.0%2.03.00.040.0%

Fundamentals of Curevac

About CureVac NV

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Fundamental data was last updated by Penke on 2024-04-11 05:29:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of CureVac NV.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Curevac earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Curevac to the Biotechnology industry mean.
  • A Net Profit Margin of -369.4% means that $-3.69 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of CureVac NV:

  • The MRQ is -369.4%. The company is making a huge loss. -2
  • The TTM is -369.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-369.4%TTM-369.4%0.0%
TTM-369.4%YOY-399.8%+30.4%
TTM-369.4%5Y-432.0%+62.6%
5Y-432.0%10Y-432.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-369.4%-197.2%-172.2%
TTM-369.4%-210.4%-159.0%
YOY-399.8%-279.3%-120.5%
5Y-432.0%-436.8%+4.8%
10Y-432.0%-599.3%+167.3%
1.1.2. Return on Assets

Shows how efficient Curevac is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Curevac to the Biotechnology industry mean.
  • -28.9% Return on Assets means that Curevac generated $-0.29 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of CureVac NV:

  • The MRQ is -28.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -28.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-28.9%TTM-28.9%0.0%
TTM-28.9%YOY-35.5%+6.6%
TTM-28.9%5Y-41.2%+12.3%
5Y-41.2%10Y-41.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-28.9%-13.6%-15.3%
TTM-28.9%-12.9%-16.0%
YOY-35.5%-11.9%-23.6%
5Y-41.2%-14.2%-27.0%
10Y-41.2%-16.2%-25.0%
1.1.3. Return on Equity

Shows how efficient Curevac is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Curevac to the Biotechnology industry mean.
  • -46.7% Return on Equity means Curevac generated $-0.47 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of CureVac NV:

  • The MRQ is -46.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -46.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-46.7%TTM-46.7%0.0%
TTM-46.7%YOY-59.8%+13.1%
TTM-46.7%5Y-69.3%+22.6%
5Y-69.3%10Y-69.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-46.7%-17.0%-29.7%
TTM-46.7%-16.1%-30.6%
YOY-59.8%-15.4%-44.4%
5Y-69.3%-20.0%-49.3%
10Y-69.3%-21.1%-48.2%

1.2. Operating Efficiency of CureVac NV.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Curevac is operating .

  • Measures how much profit Curevac makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Curevac to the Biotechnology industry mean.
  • An Operating Margin of -370.0% means the company generated $-3.70  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of CureVac NV:

  • The MRQ is -370.0%. The company is operating very inefficient. -2
  • The TTM is -370.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-370.0%TTM-370.0%0.0%
TTM-370.0%YOY-400.3%+30.3%
TTM-370.0%5Y-429.1%+59.1%
5Y-429.1%10Y-429.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-370.0%-286.1%-83.9%
TTM-370.0%-224.4%-145.6%
YOY-400.3%-288.4%-111.9%
5Y-429.1%-475.2%+46.1%
10Y-429.1%-624.7%+195.6%
1.2.2. Operating Ratio

Measures how efficient Curevac is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 4.72 means that the operating costs are $4.72 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of CureVac NV:

  • The MRQ is 4.721. The company is inefficient in keeping operating costs low. -1
  • The TTM is 4.721. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ4.721TTM4.7210.000
TTM4.721YOY5.003-0.282
TTM4.7215Y5.326-0.605
5Y5.32610Y5.3260.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.7212.997+1.724
TTM4.7213.247+1.474
YOY5.0033.766+1.237
5Y5.3265.675-0.349
10Y5.3267.857-2.531

1.3. Liquidity of CureVac NV.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Curevac is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.74 means the company has $3.74 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of CureVac NV:

  • The MRQ is 3.738. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.738. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.738TTM3.7380.000
TTM3.738YOY2.628+1.111
TTM3.7385Y3.322+0.416
5Y3.32210Y3.3220.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7383.930-0.192
TTM3.7384.251-0.513
YOY2.6285.436-2.808
5Y3.3226.045-2.723
10Y3.3226.363-3.041
1.3.2. Quick Ratio

Measures if Curevac is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Curevac to the Biotechnology industry mean.
  • A Quick Ratio of 3.48 means the company can pay off $3.48 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of CureVac NV:

  • The MRQ is 3.483. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.483. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.483TTM3.4830.000
TTM3.483YOY2.346+1.137
TTM3.4835Y3.364+0.120
5Y3.36410Y3.3640.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.4833.629-0.146
TTM3.4834.065-0.582
YOY2.3465.397-3.051
5Y3.3645.993-2.629
10Y3.3646.277-2.913

1.4. Solvency of CureVac NV.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Curevac assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Curevac to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.38 means that Curevac assets are financed with 38.0% credit (debt) and the remaining percentage (100% - 38.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of CureVac NV:

  • The MRQ is 0.380. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.380. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.380TTM0.3800.000
TTM0.380YOY0.406-0.025
TTM0.3805Y0.678-0.297
5Y0.67810Y0.6780.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3800.332+0.048
TTM0.3800.334+0.046
YOY0.4060.268+0.138
5Y0.6780.366+0.312
10Y0.6780.390+0.288
1.4.2. Debt to Equity Ratio

Measures if Curevac is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Curevac to the Biotechnology industry mean.
  • A Debt to Equity ratio of 61.4% means that company has $0.61 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of CureVac NV:

  • The MRQ is 0.614. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.614. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.614TTM0.6140.000
TTM0.614YOY0.682-0.069
TTM0.6145Y1.067-0.454
5Y1.06710Y1.0670.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6140.381+0.233
TTM0.6140.390+0.224
YOY0.6820.334+0.348
5Y1.0670.434+0.633
10Y1.0670.466+0.601

2. Market Valuation of CureVac NV

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Curevac generates.

  • Above 15 is considered overpriced but always compare Curevac to the Biotechnology industry mean.
  • A PE ratio of -5.09 means the investor is paying $-5.09 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of CureVac NV:

  • The EOD is -2.061. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.093. Based on the earnings, the company is expensive. -2
  • The TTM is -5.093. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.061MRQ-5.093+3.032
MRQ-5.093TTM-5.0930.000
TTM-5.093YOY-17.528+12.435
TTM-5.0935Y-30.936+25.843
5Y-30.93610Y-30.9360.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.061-2.315+0.254
MRQ-5.093-2.560-2.533
TTM-5.093-2.664-2.429
YOY-17.528-4.122-13.406
5Y-30.936-6.258-24.678
10Y-30.936-6.108-24.828
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of CureVac NV:

  • The EOD is -1.353. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.343. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.343. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.353MRQ-3.343+1.990
MRQ-3.343TTM-3.3430.000
TTM-3.343YOY-8.381+5.038
TTM-3.3435Y4.834-8.177
5Y4.83410Y4.8340.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.353-3.067+1.714
MRQ-3.343-3.251-0.092
TTM-3.343-3.545+0.202
YOY-8.381-5.595-2.786
5Y4.834-8.315+13.149
10Y4.834-8.708+13.542
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Curevac is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.38 means the investor is paying $2.38 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of CureVac NV:

  • The EOD is 0.962. Based on the equity, the company is cheap. +2
  • The MRQ is 2.378. Based on the equity, the company is underpriced. +1
  • The TTM is 2.378. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.962MRQ2.378-1.416
MRQ2.378TTM2.3780.000
TTM2.378YOY10.482-8.104
TTM2.3785Y7.366-4.988
5Y7.36610Y7.3660.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.9621.905-0.943
MRQ2.3782.111+0.267
TTM2.3782.095+0.283
YOY10.4822.836+7.646
5Y7.3663.443+3.923
10Y7.3663.794+3.572
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of CureVac NV.

3.1. Institutions holding CureVac NV

Institutions are holding 23.788% of the shares of CureVac NV.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Citadel Advisors Llc1.37280.0045307399372019330.597
2023-12-31RA Capital Management, LLC1.22550.18052744270-7860074-74.1213
2023-12-31Millennium Management LLC1.21870.005272890392082250.9281
2023-12-31T. Rowe Price Associates, Inc.1.0380.00132324274-863425-27.0862
2023-12-31BlackRock Inc0.80630.00021805596-16934-0.9291
2023-12-31Camber Capital Management LLC0.78150.1878175000000
2023-12-31Bill & Melinda Gates Foundation0.72617.5974162594300
2023-09-30Alyeska Investment Group, L.P.0.55040.0572123257733315437.0409
2023-12-31Walleye Trading Advisors, LLC0.34220.006876631536968593.2065
2023-12-31Goldman Sachs Group Inc0.33030.000373958022357843.3289
2023-12-31Morgan Stanley - Brokerage Accounts0.23750.0002531712330410164.1365
2023-12-31Junked Platinum Investment Management Ltd0.22240.085149790613462637.0585
2023-12-31Eversept Partners, LLC0.22190.1838496912-19882-3.8472
2023-12-31NORGES BANK0.13780.0002308675-182223-37.1203
2023-12-31Credit Suisse First Boston (CSFB)0.13570.0012303859-673-0.221
2023-12-31Adage Capital Partners Gp LLC0.11090.00222484282484280
2023-12-31Geode Capital Management, LLC0.09020.000120200026701.3395
2023-12-31Swiss National Bank0.08870.0006198547-22859-10.3245
2023-12-31Susquehanna International Group, LLP0.07960.0001178172-45201-20.2357
2023-12-31UBS Group AG0.05890.00021318725631674.5354
Total 9.77548.314721889534-5671389-25.9%

3.2. Funds holding CureVac NV

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31T. Rowe Price New Horizons0.82060.0313183761143930031.4165
2023-12-31US Small-Cap Growth II Equity Comp0.82060.0312183761143930031.4165
2024-03-28iShares Biotechnology ETF0.3030.026967845300
2024-03-28iShares Core MSCI EAFE ETF0.2480.001555542800
2024-02-29BlackRock Health Sciences Opps Inv A0.1840.016641206100
2024-03-28iShares MSCI EAFE Small-Cap ETF0.16110.011336067000
2023-12-31T. Rowe Price New Horizons Tr-Z0.14420.031432290111300053.8349
2024-02-29BlackRock Health Sciences Term Trust0.1430.056132012300
2024-03-31State St Gbl Sm Cp Eq ex-US Indx NL Cl A0.09480.006621226100
2024-03-29iShares MSCI EMU Small Cap ETF EUR Acc0.07160.059516032600
2024-03-31iShares Genomics Immnlgy & Hlthcr ETF0.07050.339115784000
2024-02-29Fidelity Nasdaq Composite Index0.0580.002912980000
2023-06-30TD Health Sciences - I0.0560.0966125347-33407-21.0432
2023-06-30DekaLux-BioTech CF0.05360.37691200001200000
2024-03-29iShares Nasdaq US Biotech ETF USD Acc0.0530.068911878900
2024-03-31Sigma Inv. House FCP Equity Eurp A Cl0.05081.766111385800
2024-03-31State St Gbl All Cp Eq ex-US Idx NL Cl K0.04350.000997475-384-0.3924
2024-03-31BlackRock MSCI ACWI ex-U.S. IMI Idx NL F0.03870.001867312280.2636
2024-03-31BlackRock MSCI ACWI ex-U.S. IMI Idx F0.03770.0018434212501.5044
2024-01-31CREF Stock R10.03720.00038321900
Total 3.48992.92617814846+1079287+13.8%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of CureVac NV compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.738-0.7380%-0.109-85%0.507-246%0.507-246%
Book Value Per Share--2.5352.5350%3.273-23%1.828+39%1.828+39%
Current Ratio--3.7383.7380%2.628+42%3.322+13%3.322+13%
Debt To Asset Ratio--0.3800.3800%0.406-6%0.678-44%0.678-44%
Debt To Equity Ratio--0.6140.6140%0.682-10%1.067-43%1.067-43%
Dividend Per Share----0%-0%-0%-0%
Eps---1.184-1.1840%-1.957+65%-0.914-23%-0.914-23%
Free Cash Flow Per Share---1.804-1.8040%-4.094+127%-0.907-50%-0.907-50%
Free Cash Flow To Equity Per Share---1.503-1.5030%-2.454+63%0.326-562%0.326-562%
Gross Profit Margin--1.0021.0020%1.0040%1.009-1%1.009-1%
Intrinsic Value_10Y_max---30.258--------
Intrinsic Value_10Y_min---25.341--------
Intrinsic Value_1Y_max---1.609--------
Intrinsic Value_1Y_min---1.563--------
Intrinsic Value_3Y_max---5.918--------
Intrinsic Value_3Y_min---5.570--------
Intrinsic Value_5Y_max---11.536--------
Intrinsic Value_5Y_min---10.503--------
Market Cap546374560.000-147%1350261720.0001350261720.0000%7682832440.000-82%5437322568.000-75%5437322568.000-75%
Net Profit Margin---3.694-3.6940%-3.998+8%-4.320+17%-4.320+17%
Operating Margin---3.700-3.7000%-4.003+8%-4.291+16%-4.291+16%
Operating Ratio--4.7214.7210%5.003-6%5.326-11%5.326-11%
Pb Ratio0.962-147%2.3782.3780%10.482-77%7.366-68%7.366-68%
Pe Ratio-2.061+60%-5.093-5.0930%-17.528+244%-30.936+507%-30.936+507%
Price Per Share2.440-147%6.0306.0300%34.310-82%24.282-75%24.282-75%
Price To Free Cash Flow Ratio-1.353+60%-3.343-3.3430%-8.381+151%4.834-169%4.834-169%
Price To Total Gains Ratio-3.306+60%-8.171-8.1710%-315.537+3762%-100.366+1128%-100.366+1128%
Quick Ratio--3.4833.4830%2.346+48%3.364+4%3.364+4%
Return On Assets---0.289-0.2890%-0.355+23%-0.412+42%-0.412+42%
Return On Equity---0.467-0.4670%-0.598+28%-0.693+48%-0.693+48%
Total Gains Per Share---0.738-0.7380%-0.109-85%0.507-246%0.507-246%
Usd Book Value--567701143.800567701143.8000%732951549.600-23%409308252.440+39%409308252.440+39%
Usd Book Value Change Per Share---0.738-0.7380%-0.109-85%0.507-246%0.507-246%
Usd Book Value Per Share--2.5352.5350%3.273-23%1.828+39%1.828+39%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---1.184-1.1840%-1.957+65%-0.914-23%-0.914-23%
Usd Free Cash Flow---403908175.400-403908175.4000%-916651473.400+127%-202997289.240-50%-202997289.240-50%
Usd Free Cash Flow Per Share---1.804-1.8040%-4.094+127%-0.907-50%-0.907-50%
Usd Free Cash Flow To Equity Per Share---1.503-1.5030%-2.454+63%0.326-562%0.326-562%
Usd Market Cap546374560.000-147%1350261720.0001350261720.0000%7682832440.000-82%5437322568.000-75%5437322568.000-75%
Usd Price Per Share2.440-147%6.0306.0300%34.310-82%24.282-75%24.282-75%
Usd Profit---265116273.400-265116273.4000%-438312853.600+65%-204601854.360-23%-204601854.360-23%
Usd Revenue--71775332.00071775332.0000%109643154.000-35%53144193.240+35%53144193.240+35%
Usd Total Gains Per Share---0.738-0.7380%-0.109-85%0.507-246%0.507-246%
 EOD+3 -5MRQTTM+0 -0YOY+20 -145Y+17 -1710Y+17 -17

4.2. Fundamental Score

Let's check the fundamental score of CureVac NV based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.061
Price to Book Ratio (EOD)Between0-10.962
Net Profit Margin (MRQ)Greater than0-3.694
Operating Margin (MRQ)Greater than0-3.700
Quick Ratio (MRQ)Greater than13.483
Current Ratio (MRQ)Greater than13.738
Debt to Asset Ratio (MRQ)Less than10.380
Debt to Equity Ratio (MRQ)Less than10.614
Return on Equity (MRQ)Greater than0.15-0.467
Return on Assets (MRQ)Greater than0.05-0.289
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of CureVac NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5024.421
Ma 20Greater thanMa 502.912
Ma 50Greater thanMa 1003.189
Ma 100Greater thanMa 2003.809
OpenGreater thanClose2.550
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets860,472
Total Liabilities327,219
Total Stockholder Equity533,253
 As reported
Total Liabilities 327,219
Total Stockholder Equity+ 533,253
Total Assets = 860,472

Assets

Total Assets860,472
Total Current Assets584,029
Long-term Assets276,443
Total Current Assets
Cash And Cash Equivalents 495,797
Short-term Investments 4,487
Net Receivables 39,437
Inventory 23,989
Other Current Assets 5,345
Total Current Assets  (as reported)584,029
Total Current Assets  (calculated)569,055
+/- 14,974
Long-term Assets
Property Plant Equipment 241,702
Goodwill 12,463
Intangible Assets 19,315
Other Assets 2,974
Long-term Assets  (as reported)276,443
Long-term Assets  (calculated)276,454
+/- 11

Liabilities & Shareholders' Equity

Total Current Liabilities156,225
Long-term Liabilities170,994
Total Stockholder Equity533,253
Total Current Liabilities
Short-term Debt 4,980
Accounts payable 68,246
Other Current Liabilities 46,219
Total Current Liabilities  (as reported)156,225
Total Current Liabilities  (calculated)119,445
+/- 36,780
Long-term Liabilities
Capital Lease Obligations 42,086
Long-term Liabilities Other 19
Deferred Long Term Liability 302
Long-term Liabilities  (as reported)170,994
Long-term Liabilities  (calculated)42,407
+/- 128,587
Total Stockholder Equity
Common Stock23,400
Retained Earnings -1,305,814
Accumulated Other Comprehensive Income 1,817,148
Other Stockholders Equity -1,481
Total Stockholder Equity (as reported)533,253
Total Stockholder Equity (calculated)533,253
+/-0
Other
Capital Stock23,400
Cash and Short Term Investments 500,284
Common Stock Shares Outstanding 189,075
Current Deferred Revenue36,780
Liabilities and Stockholders Equity 860,472
Net Debt -453,711
Net Invested Capital 533,253
Net Tangible Assets 501,486
Net Working Capital 427,804
Property Plant and Equipment Gross 258,653
Short Long Term Debt Total 42,086



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-31
> Total Assets 
125,659
130,620
1,511,356
1,158,242
860,472
860,4721,158,2421,511,356130,620125,659
   > Total Current Assets 
73,070
57,175
1,389,854
940,019
584,029
584,029940,0191,389,85457,17573,070
       Cash And Cash Equivalents 
21,380
30,684
1,322,593
811,464
495,797
495,797811,4641,322,59330,68421,380
       Short-term Investments 
39,253
1,458
2,619
4,648
4,487
4,4874,6482,6191,45839,253
       Net Receivables 
6,858
17,686
1,822
18,504
39,437
39,43718,5041,82217,6866,858
       Inventory 
2,951
6,197
14,531
56,159
23,989
23,98956,15914,5316,1972,951
       Other Current Assets 
2,628
1,150
48,289
49,244
5,345
5,34549,24448,2891,1502,628
   > Long-term Assets 
52,589
73,445
121,502
218,223
276,443
276,443218,223121,50273,44552,589
       Property Plant Equipment 
45,493
66,780
104,791
200,393
241,702
241,702200,393104,79166,78045,493
       Goodwill 
0
0
0
0
12,463
12,4630000
       Intangible Assets 
6,213
5,698
14,146
13,238
19,315
19,31513,23814,1465,6986,213
       Long-term Assets Other 
1
967
1,086
1,216
1,666
1,6661,2161,0869671
> Total Liabilities 
93,576
173,422
800,009
469,766
327,219
327,219469,766800,009173,42293,576
   > Total Current Liabilities 
28,130
28,086
247,622
357,734
156,225
156,225357,734247,62228,08628,130
       Short-term Debt 
217
2,004
3,234
3,469
4,980
4,9803,4693,2342,004217
       Accounts payable 
9,029
5,331
17,623
122,263
68,246
68,246122,26317,6235,3319,029
       Other Current Liabilities 
13,107
13,270
68,780
176,252
46,219
46,219176,25268,78013,27013,107
   > Long-term Liabilities 
65,446
145,336
552,387
112,032
170,994
170,994112,032552,387145,33665,446
       Capital Lease Obligations 
0
14,130
55,276
28,892
42,086
42,08628,89255,27614,1300
       Other Liabilities 
65,446
68,192
500,345
86,609
0
086,609500,34568,19265,446
> Total Stockholder Equity
32,083
-42,802
711,347
688,476
533,253
533,253688,476711,347-42,80232,083
   Common Stock
727
727
21,655
22,454
23,400
23,40022,45421,655727727
   Retained Earnings -1,305,814-1,056,785-645,069-515,947-416,074
   Accumulated Other Comprehensive Income 
447,430
472,418
1,334,761
1,728,624
1,817,148
1,817,1481,728,6241,334,761472,418447,430
   Capital Surplus 00000
   Treasury Stock00000



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue42,880
Cost of Revenue-150,770
Gross Profit-107,890-107,890
 
Operating Income (+$)
Gross Profit-107,890
Operating Expense-352,018
Operating Income-309,138-459,908
 
Operating Expense (+$)
Research Development109,979
Selling General Administrative78,418
Selling And Marketing Expenses-
Operating Expense352,018188,397
 
Net Interest Income (+$)
Interest Income12,921
Interest Expense-7,449
Other Finance Cost-0
Net Interest Income5,472
 
Pretax Income (+$)
Operating Income-309,138
Net Interest Income5,472
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-302,231-310,574
EBIT - interestExpense = -7,449
-302,298
-294,849
Interest Expense7,449
Earnings Before Interest and Taxes (EBIT)--294,782
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-302,231
Tax Provision-67
Net Income From Continuing Ops-302,298-302,298
Net Income-302,298
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net1,436-5,472
 

Technical Analysis of Curevac
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Curevac. The general trend of Curevac is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Curevac's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of CureVac NV.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.76 < 2.815 < 3.26.

The bearish price targets are: .

Tweet this
CureVac NV Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of CureVac NV. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

CureVac NV Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of CureVac NV. The current macd is -0.1730149.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Curevac price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Curevac. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Curevac price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
CureVac NV Daily Moving Average Convergence/Divergence (MACD) ChartCureVac NV Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of CureVac NV. The current adx is 26.77.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Curevac shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
CureVac NV Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of CureVac NV. The current sar is 3.05135358.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
CureVac NV Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of CureVac NV. The current rsi is 24.42. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
CureVac NV Daily Relative Strength Index (RSI) ChartCureVac NV Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of CureVac NV. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Curevac price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
CureVac NV Daily Stochastic Oscillator ChartCureVac NV Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of CureVac NV. The current cci is -226.62746659.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
CureVac NV Daily Commodity Channel Index (CCI) ChartCureVac NV Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of CureVac NV. The current cmo is -63.01731215.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
CureVac NV Daily Chande Momentum Oscillator (CMO) ChartCureVac NV Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of CureVac NV. The current willr is -100.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
CureVac NV Daily Williams %R ChartCureVac NV Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of CureVac NV.

CureVac NV Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of CureVac NV. The current atr is 0.17386237.

CureVac NV Daily Average True Range (ATR) ChartCureVac NV Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of CureVac NV. The current obv is -32,637,198.

CureVac NV Daily On-Balance Volume (OBV) ChartCureVac NV Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of CureVac NV. The current mfi is 49.76.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
CureVac NV Daily Money Flow Index (MFI) ChartCureVac NV Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for CureVac NV.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-21RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-23BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-18BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-20RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

CureVac NV Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of CureVac NV based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5024.421
Ma 20Greater thanMa 502.912
Ma 50Greater thanMa 1003.189
Ma 100Greater thanMa 2003.809
OpenGreater thanClose2.550
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Curevac with someone you think should read this too:
  • Are you bullish or bearish on Curevac? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Curevac? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about CureVac NV

I send you an email if I find something interesting about CureVac NV.


Comments

How you think about this?

Leave a comment

Stay informed about CureVac NV.

Receive notifications about CureVac NV in your mailbox!